Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by stock analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, MarketBeat.com reports. The brokerage presently has a $46.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 37.97% from the stock’s previous close.

COLL has been the subject of several other research reports. Piper Sandler reissued a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $43.80.

Collegium Pharmaceutical Stock Up 14.4 %

Shares of COLL stock opened at $33.34 on Friday. The stock has a market cap of $1.08 billion, a P/E ratio of 14.37 and a beta of 0.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a fifty day moving average price of $30.57 and a 200 day moving average price of $34.04. Collegium Pharmaceutical has a one year low of $28.39 and a one year high of $42.29.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of COLL. TD Private Client Wealth LLC boosted its holdings in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares in the last quarter. Foundry Partners LLC raised its position in Collegium Pharmaceutical by 3.3% in the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the last quarter. CWM LLC boosted its stake in Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its holdings in shares of Collegium Pharmaceutical by 4.4% during the third quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company’s stock worth $908,000 after purchasing an additional 983 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.